RGS2 C1114G polymorphism and body weight gain in hypertensive patients

Metabolism: Clinical and Experimental
Michelangelo SartoriHARVEST Group


RGS2 is a negative regulator of Galpha protein signaling and promotes adipocyte differentiation. Recently, we described a polymorphism at the C1114G locus with the G allele associated with hypertension in a cross-sectional study. The aim of the present study was to assess whether the RGS2 C1114G is predictive of overweight in young subjects with grade I hypertension. We genotyped at the RGS2 C1114G locus 406 (male, n = 294; female, n = 112) white hypertensive subjects (age, 33 +/- 9 years) never treated for hypertension and at low cardiovascular risk. Median follow-up was 7.85 years. At baseline, male patients carrying the RGS2 1114G allele had higher body mass index (BMI) than patients with CC genotype (26.1 +/- 0.3 vs 25.3 +/- 0.3 kg/m2, P < .05). The frequency of male patients with BMI > or = 25 was similar between the patients with G allele and those with CC genotype (55.1% vs 47.8%, P = not significant). No significant difference between the 2 groups was observed with regard to physical activity, blood pressure, and heart rate. At the end of follow-up, BMI was higher in male patients with G allele compared with patients with CC genotype (26.8 +/- 0.3 vs 25.8 +/- 0.2 kg/m2, P < .01); and the frequency of male patients with ...Continue Reading


Oct 1, 1989·Cardiovascular Drugs and Therapy·J R Hampton
Jan 1, 1997·Annual Review of Biochemistry·S R Sprang
Feb 7, 1998·Proceedings of the National Academy of Sciences of the United States of America·S P HeximerJ R Hepler
Jan 27, 1999·Biochemical and Biophysical Research Communications·M ImagawaT Nishihara
Nov 24, 1999·The Journal of Biological Chemistry·S P HeximerK J Blumer
Mar 22, 2002·The International Journal of Biochemistry & Cell Biology·John H Kehrl, Srikumar Sinnarajah
Feb 18, 2003·The Journal of Clinical Investigation·Scott P HeximerKendall J Blumer
Mar 30, 2004·Diabetes·Carl D LangefeldUNKNOWN Insulin Resistance Atherosclerosis Study Family Study
Sep 15, 2004·European Journal of Endocrinology·Markus EszlingerRalf Paschke
Apr 19, 2005·Obesity Research·Louis PérusseClaude Bouchard
Apr 6, 2006·JAMA : the Journal of the American Medical Association·Cynthia L OgdenKatherine M Flegal
Apr 29, 2006·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Dominique Langin
Sep 22, 2006·Human Molecular Genetics·Andrew J WalleyPhilippe Froguel
Nov 11, 2006·BMJ : British Medical Journal·Sarah H Wild, Christopher D Byrne

❮ Previous
Next ❯


Dec 2, 2011·PloS One·Jeffrey L WaughAbraham Kovoor
May 28, 2011·Archives of Biochemistry and Biophysics·Guillaume Bastin, Scott P Heximer
Jan 8, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jian YaoXianghuo He
Apr 10, 2009·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·M SartoriG Palareti
Aug 26, 2016·BMC Genetics·Tiina KarppanenHannele Laivuori
Dec 14, 2018·The Journal of Biological Chemistry·Laura J SharpeAndrew J Brown
Oct 14, 2020·Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids·Nicola A ScottAndrew J Brown

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.